Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 13/20 | 0.67 |
| ▸ | CA9 | Q16790 | 10/20 | 0.67 |
| ▸ | CA1 | P00915 | 10/20 | 0.67 |
| ▸ | CA5A | P35218 | 4/20 | 0.67 |
| ▸ | CA5B | Q9Y2D0 | 4/20 | 0.67 |
| ▸ | CA4 | P22748 | 3/20 | 0.67 |
| ▸ | F2 | P00734 | 1/20 | 0.60 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.60 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.60 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.60 |
| ▸ | CA12 | O43570 | 8/20 | 0.59 |
| ▸ | CA14 | Q9ULX7 | 6/20 | 0.59 |
| ▸ | CA6 | P23280 | 3/20 | 0.59 |
| ▸ | CA7 | P43166 | 3/20 | 0.59 |
| ▸ | CA3 | P07451 | 2/20 | 0.59 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.59 |
| ▸ | TMPRSS6 | Q8IU80 | 2/20 | 0.53 |
| ▸ | CA13 | Q8N1Q1 | 2/20 | 0.50 |
| ▸ | USP2 | O75604 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12652094 | 0.82 | CA2 (0.67) | CA2CA9CA1CA5ACA5B | |
| SCHEMBL4718975 | 0.82 | F2 (0.60) | CA2CA9CA1CA5ACA5B | |
| SCHEMBL1818606 | 0.80 | PRSS1 (0.58) | F2PRSS1PRSS2PRSS3CYP2C19 | |
| SCHEMBL7106023 | 0.80 | F2 (0.58) | CA2CA9CA1CA5ACA5B | |
| SCHEMBL423771 | 0.80 | F2 (0.58) | CA2CA9CA1CA5ACA5B | |
| SCHEMBL176891 | 0.79 | CA2 (1.00) | CA2CA9CA1CA5ACA5B | |
| Hydrochloric Acid SCHEMBL4176794 | 0.78 | PRSS1 (0.56) | F2PRSS1PRSS2PRSS3TMPRSS6 | |
| SCHEMBL1804314 | 0.77 | CA2 (0.65) | CA2CA9CA1CA5ACA5B | |
| SCHEMBL3824136 | 0.77 | CA2 (0.65) | CA2CA9CA1CA5ACA5B | |
| Sulfanilamide SCHEMBL8965155 | 0.77 | CA2 (0.77) | CA2CA9CA1CA5ACA5B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-1994027958-A1 | 4-AMIDINOPHENYLSULPHONAMIDES FOR THE TREATMENT OF THROMBO-EMBOLITIC CONDITIONS | BOEHRINGER MANNHEIM GMBH (DE) | 1994-12-08 | — | — | WO | claimed |
| CN-108977482-B | Preparation method of polymyxin B sulfate | 浙江孚诺医药股份有限公司 | 2020-11-24 | — | — | CN | disclosed |
| US-7994225-B2 | Combination of an antibiotic and a drug such as pentamidine or salts thereof to treat drug resistant eye and ear infections | REMPEX PHARMACEUTICALS, INC. (US) | 2011-08-09 | — | — | US | disclosed |
| US-20080132457-A1 | BACTERIAL EFFLUX PUMP INHIBITORS FOR THE TREATMENT OF OPHTHALMIC AND OTIC INFECTIONS | SILICON VALLEY BANK | 2008-06-05 | — | — | US | disclosed |
| EP-1216230-B1 | FUSED CYCLOHEPTANE AND FUSED AZACYCLOHEPTANE COMPOUNDS AND THEIR USE AS INTEGRIN RECEPTOR ANTAGONISTS | AMGEN INC (US) | 2008-04-23 | — | — | EP | disclosed |
| WO-1994027958-A1 | 4-AMIDINOPHENYLSULPHONAMIDES FOR THE TREATMENT OF THROMBO-EMBOLITIC CONDITIONS | BOEHRINGER MANNHEIM GMBH (DE) | 1994-12-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080132457-A1 | BACTERIAL EFFLUX PUMP INHIBITORS FOR THE TREATMENT OF OPHTHALMIC AND OTIC INFECTIONS | ABCB11, SLC47A2, SLC47A1 | CA2 1445/4885CA9 1871/4885CA1 4695/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.